Anesthetic management of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A case report
- PMID: 37260654
- PMCID: PMC10228853
- DOI: 10.4103/sja.sja_682_22
Anesthetic management of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A case report
Abstract
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can significantly influence overall and disease-free survival in selected patients suffering from peritoneal surface malignancies (PSMs). We report here the anaesthetic management of a 52 year old patient of Ca Colon with secondary ovarian and peritoneal deposits. She underwent cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with curative intent. The advent of CRS/HIPEC gives a promising alternative to conventional treatment modalities but comes with numerous challenges to the anesthesiologist-in view of the metabolic and hemodynamic adjustments-and demands training.
Keywords: Colloids; crystalloids; cytoreductive surgery; epidural block; general anesthesia; hyperthermic intraperitoneal chemotherapy.
Copyright: © 2023 Saudi Journal of Anesthesia.
Conflict of interest statement
There are no conflicts of interest.
References
-
- Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: A population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134:622–8. - PubMed
-
- Elias D, Goéré D, Dumont F, Honoré C, Dartigues P, Stoclin A, et al. Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer. 2014;50:332–40. - PubMed
-
- Esquivel J, Angulo F, Bland RK, Stephens AD, Sugarbaker PH. Hemodynamic, cardiac function parameters during heated intraoperative intraperitoneal chemotherapy using the open “coliseum technique”. Ann Surg Ocol. 2000;7:296–300. - PubMed
-
- Yamamoto Y, Watanabe K, Tsukiyama I, Yabushita H, Matsuura K, Wakatsuki A. Hydration with 15 mEqmagnesium is effective at reducing therisk for cisplatin-induced nephrotoxicity in patients receiving cisplatin (≥50 mg/m2) combination chemotherapy. Anticancer Res. 2016;36:1873–7. - PubMed
Publication types
LinkOut - more resources
Full Text Sources